Company Overview of Nile Therapeutics, Inc
As of November 20, 2013, Nile Therapeutics, Inc was acquired by Capricor, Inc. Nile Therapeutics, Inc., a development stage biopharmaceutical company, develops pharmaceutical products for the treatment of cardiovascular and renal diseases. Its lead product candidate include Cenderitide, a chimeric natriuretic peptide that has completed Phase I clinical trial for the treatment of patients following admission for acutely decompensated heart failure. The company also develops CU-NP, a natriuretic peptide, which is in pre-clinical studies for the treatment of cardiovascular and renal diseases. Nile Therapeutics, Inc. was founded in 2005 and is based in San Mateo, California.
63 Bovet Road
San Mateo, CA 94402
Founded in 2005
Key Executives for Nile Therapeutics, Inc
Nile Therapeutics, Inc does not have any Key Executives recorded.
Nile Therapeutics, Inc Key Developments
Nile Therapeutics, Inc will Change its Ticker to NLTXD from NLTX
Nov 20 13
Effective November 21, 2013, Nile Therapeutics, Inc will change its Pink Sheets LLC stock ticker symbol to NLTXD from NLTX.
Nile Therapeutics, Inc Proposes Amendment to Certificate of Incorporation
Oct 10 13
The Special Meeting of Stockholders of Nile Therapeutics Inc. will be held on November 12, 2013. At the meeting the shareholders proposes amendment of the company's certificate of incorporation to effect a combination (reverse split) of the company's common stock; and amendment to change the company's name from Nile Therapeutics Inc. to Capricor Therapeutics Inc.
Nile Therapeutics, Inc, Special/Extraordinary Shareholders Meeting, Nov 12, 2013
Oct 10 13
Nile Therapeutics, Inc, Special/Extraordinary Shareholders Meeting, Nov 12, 2013., at 09:00 Pacific Standard Time. Location: Bay Club, 3rd Floor Conference Room, 645 5th Street. Agenda: To authorize the amendment of the company’s certificate of incorporation to effect a combination (reverse split) of the company’s common stock at a ratio not to exceed 1:100 (the reverse stock split), and to reduce the total number of shares of common stock that are authorized to issue from 100 million to 50 million and reduce the total number of shares of preferred stock that are authorized to issue from 10 million to 5 million (the share reduction); to authorize the amendment of the company’s certificate of incorporation to change the company’s name from Nile Therapeutics, Inc. to Capricor Therapeutics, Inc.; to approve adjournments of the special meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the Charter amendment proposals; and to approve, on a nonbinding, advisory basis, the golden parachute compensation that may be paid or become payable to the company’s named executive officers in connection with the consummation of the Merger.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|